No Data
No Data
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Editas Medicine Shares Jump as Potential Gene Therapy for Sickle Cell Disease Found to Be 'Well-Tolerated'
Editas Medicine Presents Data From RUBY Trial At ASH 2024, Showing Reni-Cel Achieves 96% VOE-Free Rate, Sustained Increases In Hemoglobin And Fetal Hemoglobin, And Clinically Meaningful Pain And Function Improvements In Severe Sickle Cell Patients;...
Express News | Editas Medicine Reports Updated Clinical Data From the Ruby Trial of Reni-Cel in Patients With Severe Sickle Cell Disease at the American Society of Hematology (Ash) Annual Meeting
Editas Medicine Reports Updated Clinical Data From the RUBY Trial of Reni-cel in Patients With Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)
Unlock the Full List